George I Papakostas

Summary

Publications

  1. ncbi request reprint A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 26:56-60. 2006
  2. ncbi request reprint Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 65:1096-8. 2004
  3. ncbi request reprint Psychosocial functioning during the treatment of major depressive disorder with fluoxetine
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 24:507-11. 2004
  4. doi request reprint Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine
    Huaiyu Yang
    Department of Psychiatry, Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114, USA
    Eur Arch Psychiatry Clin Neurosci 260:145-50. 2010
  5. ncbi request reprint Nortriptyline for treatment-resistant depression
    Andrew A Nierenberg
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, 02114, USA
    J Clin Psychiatry 64:35-9. 2003
  6. ncbi request reprint Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 65:1090-5. 2004
  7. ncbi request reprint Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Ann Clin Psychiatry 15:187-92. 2003
  8. ncbi request reprint The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    Int J Neuropsychopharmacol 8:523-8. 2005
  9. ncbi request reprint Obesity among outpatients with major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    Int J Neuropsychopharmacol 8:59-63. 2005
  10. ncbi request reprint Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1326-30. 2005

Detail Information

Publications98

  1. ncbi request reprint A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 26:56-60. 2006
    ....
  2. ncbi request reprint Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 65:1096-8. 2004
    ....
  3. ncbi request reprint Psychosocial functioning during the treatment of major depressive disorder with fluoxetine
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 24:507-11. 2004
    ..Therefore, studying the impact of treatment on psychosocial functioning in MDD could help further improve the standard of care...
  4. doi request reprint Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine
    Huaiyu Yang
    Department of Psychiatry, Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114, USA
    Eur Arch Psychiatry Clin Neurosci 260:145-50. 2010
    ..Future studies are needed to further explore the relationship between residual symptoms and relapse risk in MDD...
  5. ncbi request reprint Nortriptyline for treatment-resistant depression
    Andrew A Nierenberg
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, 02114, USA
    J Clin Psychiatry 64:35-9. 2003
    ..This study assesses the efficacy of nortriptyline for patients with treatment-resistant major depression...
  6. ncbi request reprint Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 65:1090-5. 2004
    ....
  7. ncbi request reprint Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Ann Clin Psychiatry 15:187-92. 2003
    ..These findings failed to reveal any relationship between side effects and treatment outcome for patients with MDD enrolled in an 8-week, 20 mg, fixed dose, open trial of fluoxetine...
  8. ncbi request reprint The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    Int J Neuropsychopharmacol 8:523-8. 2005
    ..05). In conclusion, low serum folate levels were found to be associated with a delayed onset of clinical improvement during treatment with fluoxetine in MDD by, on average, 1.5 wk...
  9. ncbi request reprint Obesity among outpatients with major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    Int J Neuropsychopharmacol 8:59-63. 2005
    ..Greater relative body weight, but not obesity, predicted non-response. In conclusion, greater relative body weight was found to place MDD outpatients at risk for fluoxetine resistance...
  10. ncbi request reprint Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1326-30. 2005
    ..The purpose of this study was to test this hypothesis in depressed outpatients who have not experienced significant clinical improvement following an adequate trial of a selective serotonin reuptake inhibitor (SSRI)...
  11. ncbi request reprint Early-onset depression and the emotional and behavioral characteristics of offspring
    Timothy J Petersen
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Depress Anxiety 18:104-8. 2003
    ..This finding may be significant in uncovering sources of vulnerability and formulating intervention strategies for offspring of depressed parents...
  12. ncbi request reprint An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 66:1038-42. 2005
    ..In an open trial, we investigated the efficacy of triiodothyronine (T(3)) adjuvant to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder (MDD) resistant to SSRI treatment...
  13. doi request reprint S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial
    George I Papakostas
    Center for Treatment Resistant Depression, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman St, Boston, MA 02114, USA
    Am J Psychiatry 167:942-8. 2010
    ....
  14. ncbi request reprint Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Psychosom Med 67:703-6. 2005
    ..In this study, we measured the impact of cardiovascular risk factors on the outcome of antidepressant treatment in major depressive disorder (MDD)...
  15. pmc Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment
    David Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    CNS Spectr 17:76-86. 2012
    ..To examine the prevalence of the C677T polymorphism of the methylene tetrahydrofolate reductase (MTHFR) gene and the A2756G polymorphism of methionine synthase (MS), and their impact on antidepressant response...
  16. ncbi request reprint Axis III disorders in treatment-resistant major depressive disorder
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WAC 812, Boston, MA 02114, USA
    Psychiatry Res 118:183-8. 2003
    ..Thus, the present results cannot be generalized to such populations...
  17. ncbi request reprint Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment
    Amy Farabaugh
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA USA
    Ann Clin Psychiatry 22:166-71. 2010
    ....
  18. ncbi request reprint Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WACC 812, Boston, MA 02214, USA
    J Clin Psychiatry 65:543-6. 2004
    ..In the present study we assessed the relationship between somatic symptoms and the time to onset of clinical response to fluoxetine in patients with major depressive disorder (MDD)...
  19. ncbi request reprint Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, WACC 812, 15 Parkman Street, Boston, Massachusetts, 02114, USA
    J Nerv Ment Dis 191:444-9. 2003
    ..Furthermore, a full 6-week trial of NT, a relatively noradrenergic tricyclic antidepressant, may be particularly useful in patients who have failed to respond to several antidepressants and also report significant hopelessness...
  20. ncbi request reprint A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Ann Clin Psychiatry 17:161-5. 2005
    ....
  21. ncbi request reprint Empirical testing of two models for staging antidepressant treatment resistance
    Timothy Petersen
    Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
    J Clin Psychopharmacol 25:336-41. 2005
    ..This study was undertaken to empirically test 2 recent models for staging treatment resistance...
  22. ncbi request reprint Brain white-matter hyperintensities and treatment outcome in major depressive disorder
    Dan V Iosifescu
    Massachusetts General Hospital, 50 Staniford Street, Suite 401, Boston, Massachusetts 02114, USA
    Br J Psychiatry 188:180-5. 2006
    ..An increased incidence of brain white-matter hyperintensities has been described in major depressive disorder, butthe impact of such hyperintensities on treatment outcome is still controversial...
  23. ncbi request reprint Anger attacks in major depressive disorder and serum levels of homocysteine
    Renerio Fraguas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Biol Psychiatry 60:270-4. 2006
    ..Increased levels of homocysteine have been associated with anger and depression separately. We investigated the association of anger attacks in major depressive disorder (MDD) with serum levels of homocysteine...
  24. ncbi request reprint Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School Boston, MA 02114, USA
    Ann Clin Psychiatry 19:5-8. 2007
    ..The purpose of this study was to study hopelessness as a predictor of response to fluoxetine in outpatients with Major Depressive Disorder (MDD)...
  25. doi request reprint Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 161:116-20. 2008
    ..Studies examining whether specific treatment strategies are more effective than the selective serotonin reuptake inhibitors for MDD patients with high levels of co-morbid psychic and somatic anxiety symptoms are warranted...
  26. ncbi request reprint Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I)
    Dan V Iosifescu
    Massachusetts General Hospital, Department of Psychiatry, Depression Clinical and Research Program, Harvard Medical School, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
    Psychiatry Res 140:291-9. 2005
    ..In light of the adverse impact of WMHs on a number of health-related outcomes later in life, hypofolatemia and hypertension may represent modifiable risk factors to prevent the occurrence of such adverse outcomes...
  27. ncbi request reprint Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies
    George I Papakostas
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 69:1287-92. 2008
    ....
  28. ncbi request reprint Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 149:195-200. 2007
    ..Further studies exploring the impact of various treatment modalities and placebo on the timing of clinical improvement and symptom resolution in MDD are warranted...
  29. ncbi request reprint Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA 02114, USA
    J Clin Psychiatry 65:217-21. 2004
    ..The purpose of this study is to test this hypothesis in depressed outpatients who have not experienced significant clinical improvement following an adequate trial of a selective serotonin reuptake inhibitor (SSRI)...
  30. pmc A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder
    David Mischoulon
    Massachusetts General Hospital, Depression Clinical and Research Program, Boston, MA 02114, USA
    J Clin Psychiatry 70:1636-44. 2009
    ..To examine the efficacy and tolerability of ethyl-eicosapentaenoate (EPA-E) monotherapy for major depressive disorder (MDD)...
  31. doi request reprint Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group
    Justin A Chen
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital MGH, Harvard Medical School, Boston, USA
    J Clin Psychiatry 72:1669-76. 2011
    ..To reanalyze data from a 2002 study by the Hypericum Depression Trial Study Group to determine whether patients who believed they were receiving active therapy rather than placebo obtained greater improvement, independent of treatment...
  32. ncbi request reprint Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine
    John W Denninger
    Massachusetts General Hospital, Depression Clinical and Research Program, Dept of Psychiatry, 50 Staniford St, Suite 401, Boston, MA 02114 2541, USA
    Psychosomatics 47:348-52. 2006
    ..Taken together, these findings suggest that developing treatment strategies that successfully target somatic symptoms of depression may further improve the ability to treat depression to remission...
  33. pmc Low-dose transdermal testosterone augmentation therapy improves depression severity in women
    Karen K Miller
    Neurendocrine Research Program in Women s Health, Neuendocrine Unit, Massachusetts General Hospital, Boston, MA, USA
    CNS Spectr 14:688-94. 2009
    ..However, the effects of low-dose testosterone as augmentation therapy in women with treatment-resistant depression have not been studied...
  34. ncbi request reprint Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment
    Dan V Iosifescu
    Depression Clinical and Research Program, Psychiatry Department, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Psychosomatics 45:419-25. 2004
    ..Greater medical comorbidity was also associated with higher increases in self-reported symptoms of depression, anxiety, and anger during the follow-up...
  35. ncbi request reprint Serum cholesterol in treatment-resistant depression
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Neuropsychobiology 47:146-51. 2003
    ....
  36. ncbi request reprint Serum cholesterol and serotonergic function in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA 02114, USA
    Psychiatry Res 118:137-45. 2003
    ....
  37. pmc Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome
    Amy H Farabaugh
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Int Clin Psychopharmacol 25:214-7. 2010
    ..Future studies are warranted to further investigate this relationship as well as that between anxious depression and treatment outcome...
  38. ncbi request reprint Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Mass 02114, USA
    J Clin Psychiatry 64:1357-61. 2003
    ..The purpose of this study was to test whether the presence of comorbid Axis I and Axis II disorders predicts clinical response to an open trial of nor-triptyline among patients with treatment-resistant depression...
  39. ncbi request reprint Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials
    George I Papakostas
    Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    J Psychiatr Res 42:134-40. 2008
    ..09, p=0.569), or HAM-A scores at endpoint (3.30+/-2.89 vs. 3.31+/-2.89, p=0.552). Contrary to clinician impression, there does not appear to be any difference in the anxiolytic efficacy of bupropion and the SSRIs when used to treat MDD...
  40. ncbi request reprint Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
    Psychiatry Res 126:287-90. 2004
    ..Pre-treatment anxiety was not related to the development of side effects...
  41. doi request reprint Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants
    Marlene P Freeman
    Perinatal and Reproductive Psychiatry Program, Massachusetts General Hospital, 185 Cambridge St, 2nd Floor, Boston, MA 02114, USA
    J Clin Psychiatry 71:682-8. 2010
    ....
  42. ncbi request reprint Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Int Clin Psychopharmacol 22:226-9. 2007
    ..This finding could, however, not be replicated when improvement in anxious/somatic symptoms was defined as a continuous measure...
  43. ncbi request reprint The combination of duloxetine and bupropion for treatment-resistant major depressive disorder
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Boston, 02114, USA
    Depress Anxiety 23:178-81. 2006
    ..Although preliminary, these results suggest a possible role for the combination of duloxetine and bupropion for TRD...
  44. pmc Relationship between sleep disturbance and depression, anxiety, and functioning in college students
    Maren Nyer
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Depress Anxiety 30:873-80. 2013
    ..We hypothesized that students with depressive symptoms with SD would demonstrate a greater burden of comorbid psychiatric symptoms and functional impairment compared to students with depressive symptoms without SD...
  45. doi request reprint Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach
    Enrico Tedeschini
    Depression Clinical and Research Program, Harvard Medical School, Massachusetts General Hospital, 50 Staniford St, Boston, MA 02114, USA
    J Clin Psychiatry 72:98-113. 2011
    ..In order to accomplish this, we examined the relationship between a "positive" or "negative" finding early on (weeks 1-4), and outcome at end point...
  46. ncbi request reprint Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 68:826-31. 2007
    ..To examine the efficacy and overall tolerability of augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder...
  47. ncbi request reprint A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 67:1754-9. 2006
    ..The purpose of the present work is to examine cross-sectionally the prevalence of cognitive and physical side effects of antidepressants during long-term treatment of depression...
  48. ncbi request reprint A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, 156 Parkman Street, WACC 812, Boston, MA 02114, USA
    Int Clin Psychopharmacol 18:293-6. 2003
    ....
  49. doi request reprint A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder
    David Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States
    Eur Neuropsychopharmacol 18:639-45. 2008
    ..05). For completers and intent-to-treat subjects, plasma DHA increased significantly (p<0.05), EPA had little change (p>0.05), and n-6/n-3 decreased significantly (p<0.05). DHA may be effective for depression at lower doses...
  50. doi request reprint Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis
    Enrico Tedeschini
    Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Eur Neuropsychopharmacol 20:562-7. 2010
    ..An increased likelihood of receiving placebo did not inflate discontinuation rates which did not influence the degree of antidepressant-placebo "separation"...
  51. ncbi request reprint Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II)
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 140:301-7. 2005
    ....
  52. ncbi request reprint Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 67:952-7. 2006
    ..To determine changes in serum prolactin levels in outpatients with DSM-IV-diagnosed major depressive disorder (MDD) following a 12-week open-label trial of fluoxetine...
  53. ncbi request reprint Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials
    George I Papakostas
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 68:1907-12. 2007
    ..The current analysis was undertaken to determine if these antidepressants differ in rapidity of clinical effect...
  54. ncbi request reprint Switching to bupropion in fluoxetine-resistant major depressive disorder
    Maurizio Fava
    The Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Ann Clin Psychiatry 15:17-22. 2003
    ..Bupropion SR should be considered as a potential treatment for patients who remain depressed despite treatment with SSRIs..
  55. doi request reprint Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study
    George I Papakostas
    Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114, USA
    Int Clin Psychopharmacol 25:17-21. 2010
    ..The efficacy of fluoxetine-clonazepam cotherapy compared with fluoxetine monotherapy was numerically but not statistically enhanced for patients with anxious depression than those without anxious depression...
  56. pmc Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder
    David Mischoulon
    Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 73:843-8. 2012
    ....
  57. doi request reprint Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial
    David Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 73:353-7. 2012
    ....
  58. ncbi request reprint Psychosocial functioning in patients with treatment resistant depression
    Timothy Petersen
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street, WAC 812 Boston, MA 02114, USA
    Eur Psychiatry 19:196-201. 2004
    ..This is particularly true for those with treatment resistant depression (TRD). However, to date, no systematic assessments of psychosocial functioning for patients with TRD have been conducted...
  59. ncbi request reprint Behavioral and emotional disturbances in the offspring of depressed parents with anger attacks
    Jonathan E Alpert
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Mass, USA
    Psychother Psychosom 72:102-6. 2003
    ..To examine the emotional and behavioral characteristics of the offspring of depressed parents with and without anger attacks...
  60. doi request reprint Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Eur Neuropsychopharmacol 19:34-40. 2009
    ..Fixed versus flexible dose design, trial duration and population age did not influence clinical trial outcome...
  61. ncbi request reprint Somatic symptoms in treatment-resistant depression
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 118:39-45. 2003
    ..The overwhelming majority of patients with TRD presented with somatic symptoms. In addition, a greater number of somatic symptoms during the screen visit placed patients at risk for further treatment resistance...
  62. ncbi request reprint Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
    Eur Neuropsychopharmacol 14:135-42. 2004
    ..We then propose possible mechanisms that would account for the relationship between elevated cholesterol and treatment non-response in MDD...
  63. doi request reprint Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Int Clin Psychopharmacol 24:19-25. 2009
    ..Clearly, further work is needed to help determine whether there are specific MDD populations that can, indeed, benefit from T3-SSRI coinitiation therapy...
  64. ncbi request reprint Use of atypical antipsychotics for treatment-resistant major depressive disorder
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
    Curr Psychiatry Rep 10:481-6. 2008
    ..This review summarizes the existing data regarding the effectiveness of these medications in treating TRD, including biochemical rationale and clinical data...
  65. ncbi request reprint Tolerability of modern antidepressants
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    J Clin Psychiatry 69:8-13. 2008
    ....
  66. ncbi request reprint Antidepressant dose reduction and the risk of relapse in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Mass 02114, USA
    Psychother Psychosom 76:266-70. 2007
    ....
  67. doi request reprint Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    World J Biol Psychiatry 11:300-7. 2010
    ..Developing treatment strategies allowing clinicians to deliver higher initial SSRI doses while enhancing the tolerability of treatment may represent an alternative approach to improving the efficacy of treatment of MDD...
  68. ncbi request reprint S-adenosyl-methionine in depression: a comprehensive review of the literature
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
    Curr Psychiatry Rep 5:460-6. 2003
    ..Finally, the authors propose a model that would explain the actions of SAMe in the central nervous system...
  69. ncbi request reprint Initial treatment approaches for patients with major depressive disorder
    George I Papakostas
    Department of Psychiatry, Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA
    J Clin Psychiatry 70:e18. 2009
    ..Factors for choosing an antidepressant include indication, efficacy, tolerability, and safety. Patient preference and treatment history should also be considered when deciding which initial treatment approach is appropriate...
  70. doi request reprint Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder
    George I Papakostas
    Department of Psychiatry, Harvard Medical School and Massachusetts General Hospital, Boston, MA 01224, USA
    J Clin Psychiatry 70:16-25. 2009
    ....
  71. doi request reprint The efficacy, tolerability, and safety of contemporary antidepressants
    George I Papakostas
    Department of Psychiatry, Harvard Medical School and Massachusetts General Hospital, Boston, MA 01224, USA
    J Clin Psychiatry 71:e03. 2010
    ..Finally, the safety profile of these agents is summarized...
  72. ncbi request reprint Augmentation strategies in the treatment of major depressive disorder. Examining the evidence on augmentation with atypical antipsychotics
    George I Papakostas
    Harvard Medical School, Boston, Massachusetts, USA
    CNS Spectr 12:10-2. 2007
  73. ncbi request reprint A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Department of Psychiatry, 15 Parkman Street, WAC 812, Harvard Medical School, Boston, Massachusetts 02114, USA
    Eur Neuropsychopharmacol 17:32-6. 2007
    ....
  74. ncbi request reprint Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis
    Amy H Farabaugh
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, USA USA
    Hum Psychopharmacol 21:221-5. 2006
    ..This study examines the relationship between cognitive factors and TDR and PPR to fluoxetine...
  75. ncbi request reprint Dopaminergic-based pharmacotherapies for depression
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Eur Neuropsychopharmacol 16:391-402. 2006
    ..In the present article we will briefly review studies focusing on the role of dopamine in depression followed by a comprehensive review of pharmacotherapies for depression with pro-dopaminergic activity...
  76. ncbi request reprint Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Biol Psychiatry 60:1350-5. 2006
    ....
  77. ncbi request reprint Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Essent Psychopharmacol 6:209-20. 2005
    ..While routinely used for psychotic depression and panic reactions in depressive disorders, their value as augmenters in TRD awaits further study...
  78. ncbi request reprint A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Can J Psychiatry 51:783-90. 2006
    ....
  79. ncbi request reprint Functioning and interpersonal relationships as predictors of response in treatment-resistant depression
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
    Compr Psychiatry 44:44-50. 2003
    ..Beyond a history of nonresponse to antidepressants, long-term occupational function may be a predictor of outcome in the treatment of TRD...
  80. ncbi request reprint Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents
    George I Papakostas
    Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114, USA
    Biol Psychiatry 62:1217-27. 2007
    ..The goal of our work was to compare response rates among patients with MDD treated with either of these two broad categories of antidepressant drugs...
  81. ncbi request reprint Treatment-resistant depression and Axis II comorbidity
    Timothy Petersen
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Mass 02114, USA
    Psychother Psychosom 71:269-74. 2002
    ....
  82. ncbi request reprint Limitations of contemporary antidepressants: tolerability
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 68:11-7. 2007
    ....
  83. doi request reprint Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder
    George I Papakostas
    Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 15 Parkman St WACC 812, Boston, MA 01224, USA
    J Clin Psychiatry 70:18-22. 2009
    ..Although preliminary data suggest SAM-e may be useful as an adjunctive therapy to antidepressants, controlled studies are needed to confirm or refute these preliminary findings...
  84. ncbi request reprint A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WAC 812, Boston, MA 02114, USA
    Eur Psychiatry 22:444-7. 2007
    ..To compare response rates among patients with major depressive disorder (MDD) treated with either a serotonin-2 (5HT2-) receptor antagonist or a selective serotonin reuptake inhibitor (SSRI)...
  85. ncbi request reprint NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients
    Timothy Petersen
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, 15 Parkman Street, WAC 812, MA, Boston 02114, USA
    Psychiatry Res 109:9-16. 2002
    ....
  86. pmc Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder
    George I Papakostas
    Depression Clinical Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Dialogues Clin Neurosci 10:439-51. 2008
    ..Biologic leads will include gene polymorphisms, brain metabolism, quantitative electroencephalography, loudness dependence of auditory evoked potentials, and functional brain asymmetry...
  87. ncbi request reprint A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WAC 812 Boston, MA 02114, USA
    Eur Neuropsychopharmacol 18:122-7. 2008
    ..These results suggest that the NRI reboxetine and the SSRIs differ with respect to their side-effect profile and overall tolerability but not their efficacy in treating MDD...
  88. ncbi request reprint Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism
    Madhusmita Misra
    Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 65:1607-18; quiz 1590, 1760-1. 2004
    ..Few reviews have thus far addressed this issue. We have consolidated information from studies that examined effects of psychiatric conditions and their treatment on bone metabolism...
  89. ncbi request reprint Quality of life assessments in major depressive disorder: a review of the literature
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Gen Hosp Psychiatry 26:13-7. 2004
    ..Exploring the impact of these modalities on psychosocial function and quality of life in MDD are necessary to help translate clinical response into restoration of psychosocial function and to thus further improve the standard of care...
  90. ncbi request reprint Extreme response style in recurrent and chronically depressed patients: change with antidepressant administration and stability during continuation treatment
    Timothy J Peterson
    Rhode Island Hospital Department of Psychiatry, Mood Disorders Program, Providence, RI 02903, USA
    J Consult Clin Psychol 75:145-53. 2007
    ..These results are consistent with recent findings suggesting that metacognitive factors may be as important as changes in thought content when treating depression...
  91. ncbi request reprint A survey of antidepressant prescribing practices in major depression with comorbid attention-deficit hyperactivity disorder
    George I Papakostas
    J Clin Psychopharmacol 26:216-8. 2006
  92. ncbi request reprint Adjunctive atomoxetine for residual fatigue in major depressive disorder
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA 02114, United States
    J Psychiatr Res 40:370-3. 2006
    ..To assess the effectiveness and safety of atomoxetine as an adjunctive medication for residual fatigue in a naturalistic treatment setting...
  93. ncbi request reprint Treatment-resistant depression
    Daniel Souery
    Department of Psychiatry, Erasme Hospital, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Psychiatry 67:16-22. 2006
    ..However, the optimal strategy for treating TRD has yet to be identified. Therefore, further controlled clinical trials are essential to identify the most effective treatment strategies...
  94. ncbi request reprint Symptoms of fatigue and sleepiness in major depressive disorder
    David S Baldwin
    Faculty of Medicine, Health, and Life Sciences, University of Southampton, UK
    J Clin Psychiatry 67:9-15. 2006
    ....
  95. doi request reprint Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA
    Acta Psychiatr Scand 117:253-9. 2008
    ..Atypical antipsychotics (AAPs) have been hypothesized to be beneficial in treatment-resistant depression (TRD). This paper will review a biochemical rationale and will summarize the data regarding the effectiveness of AAPs in TRD...
  96. doi request reprint Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Mass 02114, USA
    Neuropsychobiology 56:132-7. 2007
    ..Thirty-nine MDD outpatients who responded following a 12-week, double-blind study comparing Hypericum perforatum, fluoxetine or placebo were included in the analysis...
  97. ncbi request reprint Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Biol Psychiatry 63:699-704. 2008
    ..The goal of the present work was to conduct a meta-analysis of studies comparing these two switch strategies...
  98. ncbi request reprint Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants
    Andrew A Nierenberg
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychopharmacol 23:92-5. 2003
    ..More definitive data await the outcome of the NIMH Sequential Treatment Alternatives to Relieve Depression (STAR*D) study...